Sosa-Vizcaino A, Scheffler-Mendoza S, Hernández-Bautista VM, Dávila G, Borjas-Aguilar KL, Martínez-Pérez M, Venegas-Montoya E

Language: Spanish
References: 21
Page: 27-32
PDF size: 169.58 Kb.

ABSTRACT

In the last years new pathologies have been described, as well as the association between neurology and immunology, by which it has been proven that diseases with neurological components are triggered by an autoimmune etiology, many of them driven by inflammatory processes generating histological changes, cellular and molecular damage. Understanding the pathophysiological mechanism behind these pathologies can expand the field of treatment. In this article we describe three clinical cases of patients with neurological pathologies with an autoimmune etiology such as myasthenia gravis, myoclonic encephalopathy and autoimmune encephalitis; all three cases were refractory to first line management and due to clinical evolution they required the use of monoclonal antibodies and intravenous human immunoglobulin resulting in clinical improvement.

REFERENCES

1. Selmi C, Barin JG, Rose NR. Current trends in autoimmunity and the nervous system. J Autoimmun. 2016; 75: 20-29.

2. Becher B, Spath S, Goverman J. Cytokine networks in neuroinflammation. Nat Rev Immunol. 2017; 17 (1): 49-59.

3. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008; 4 (10): 557-567.

4. Yang ZX, Xu KL, Xiong H. Clinical characteristics and therapeutic evaluation of childhood myasthenia gravis. Exp Ther Med. 2015; 9 (4): 1363-1368.

5. Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011; 2011: 404101.

6. Pineles SL, Avery RA, Moss HE, Finkel R, Blinman T, Kaiser L et al. Visual and systemic outcomes in pediatric ocular myasthenia gravis. Am J Ophthalmol. 2010; 150 (4): 453-459.e3.

7. Lee JI, Jander S. Myasthenia gravis: recent advances in immunopathology and therapy. Expert Rev Neurother. 2016.

8. Ghia T, Kanhangad M, Alessandri AJ, Price G, Gera P, Nagarajan L. Opsoclonus-myoclonus syndrome, neuroblastoma, and insulin-dependent diabetes mellitus in a child: a unique patient. Pediatr Neurol. 2016; 55: 68-70.

9. Torres-Mayagoitia D, Dávila-Gutiérrez G, Hernández-Bautista VM, Vázquez-Estrada P, Rodríguez-Tapia J. Tratamiento de la encefalopatía mioclónica de la infancia (síndrome de Kinsbourne) con metotrexate y gammaglobulina endovenosa. Acta Pediatr Mex. 2013; 34 (6): 370-373.

10. Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics. 2011; 128 (2): e388-e394.

11. Hasegawa S, Matsushige T, Kajimoto M, Inoue H, Momonaka H, Oka M et al. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev. 2015; 37 (7): 656-660.

12. Syrbe S, Merkenschlager A, Bernhard MK, Grosche J, Liebert UG, Hirsch W et al. Opsoclonus-myoclonus syndrome after adenovirus infection. Springerplus. 2015; 4: 636.

13. Maranhao MV, de Holanda AC, Tavares FL. Kinsbourne syndrome: case report. Braz J Anesthesiol. 2013; 63 (3): 287-289.

14. Battaglia T, De Grandis E, Mirabelli-Badenier M, Boeri L, Morcaldi G, Barabino P et al. Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments. Eur J Paediatr Neurol. 2012; 16 (2): 192-195.

15. Leen WG, Weemaes CM, Verbeek MM, Willemsen MA, Rotteveel JJ. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome. Pediatr Neurol. 2008; 39 (3): 213-217.

16. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010; 62 (3): 405-496.

17. Peery HE, Day GS, Dunn S, Fritzler MJ, Pruss H, De Souza C et al. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev. 2012; 11 (12): 863-872.

18. Armangue T, Petit-Pedrol M, Dalmau J. Autoimmune encephalitis in children. J Child Neurol. 2012; 27 (11): 1460-1469.

19. Lunemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. Nat Rev Neurol. 2015; 11 (2): 80-89.

20. Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014; 83 (2): 142-150.

21. Nosadini M, Mohammad SS, Suppiej A, Sartori S, Dale RC, Group IiNS. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome. Dev Med Child Neurol. 2016; 58 (11): 1180-1192.